Dynavax Technologies (DVAX) to Release Earnings on Thursday

Dynavax Technologies (NASDAQ:DVAX) is scheduled to announce its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of $0.10 per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The business had revenue of $73.80 million for the quarter, compared to the consensus estimate of $76.92 million. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. During the same period in the prior year, the business posted $0.03 earnings per share. On average, analysts expect Dynavax Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Dynavax Technologies Price Performance

Shares of Dynavax Technologies stock opened at $12.06 on Thursday. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of 201.00 and a beta of 1.37. The company has a debt-to-equity ratio of 0.35, a quick ratio of 13.18 and a current ratio of 14.18. The stock has a 50 day moving average price of $11.03 and a 200-day moving average price of $11.21. Dynavax Technologies has a one year low of $9.74 and a one year high of $15.15.

Wall Street Analyst Weigh In

Several research firms have commented on DVAX. The Goldman Sachs Group dropped their price objective on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and set a $29.00 price target on shares of Dynavax Technologies in a report on Tuesday, October 15th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $23.67.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.